Agenus, Inc. is a clinical-stage biotechnology company focused on discovering and developing immuno-oncology therapies, with R&D centered largely on antibody programs. The company’s activities span research, preclinical and clinical development, manufacturing, regulatory and clinical affairs, and intellectual property prosecution, with a business model that mixes internal development with collaborations and licensing. A distinctive feature of its reported revenue is non-cash royalty revenue tied to GSK vaccines that include Agenus’ STIMULON QS-21 adjuvant, even though the underlying royalties were sold to a third party (HCR) and are remitted directly to HCR. Agenus’ ability to fund operations and progress programs depends heavily on clinical and regulatory outcomes, collaboration milestones, and periodic capital raises and partner funding.
−8,9 %
99,1 %
−2,7 %
+10,4 %
0.41
0.41
| % | |
|---|---|
| Antibody programs (immuno-oncology) | 55% Discovery and clinical development of antibody-based cancer immunotherapies. |
| Adjuvant-related economics (STIMULON QS-21) | 35% Economic participation in vaccine sales that include the QS-21 adjuvant via royalty arrangements. |
| Collaboration and licensing arrangements | 8% Partnering, out-licensing, and collaboration activities that can generate funding and milestones. |
| Other (access programs and services) | 2% Reimbursed compassionate access and other ancillary activities supporting development and access. |
Agenus’ primary “customers” are biopharmaceutical partners and collaborators that fund or co-develop programs, as well...
Provide funding and capabilities for clinical development and potential commercialization; Agenus trades economics for shared risk and speed.
Drive adjuvant-linked royalty economics through sales of vaccines containing STIMULON QS-21 (e.g., GSK vaccines).
Reimburse treatment supplied under compassionate access pathways, supporting limited near-term inflows and real-world use.
Support early research and translational work; often part of broader collaboration structures.
Agenus is a U.S.-based biotechnology company with operations and counterparties that are inherently international due...
Agenus’ strategy emphasizes advancing its immuno-oncology antibody programs through clinical trials while managing cash...
Regulatory approval and market acceptance are prerequisites for sustainable cash generation.
Partner funding and milestone benchmarks influence cash inflows and commercialization pathways.
Operations have been financed through partnerships, royalty monetizations, and capital markets; continued funding is required.
Agenus faces high clinical and regulatory risk because its product candidates require successful trials and approvals...
The company expects significant losses and requires additional funding beyond its projected runway; funding depends on partners and capital markets.
Collaboration agreements mean Agenus will not completely control efforts to bring candidates to market, affecting timing and outcomes.
Non-cash royalty revenue and related non-cash interest dynamics are driven by net sales and sales forecasts of vaccines containing QS-21.
AGIO · Pharmaceutical Preparations
RCUS · Pharmaceutical Preparations
Arcus Biosciences is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and, to a lesser extent, inflammatory and autoimmune diseases.
ANNX · Pharmaceutical Preparations
REPL · Biological Products, (No Diagnostic Substances)
TCRT · Pharmaceutical Preparations
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
: 11/08/2026